Expression of E-cadherin in normal oral mucosa, in oral precancerous lesions and in oral carcinomas
Open Access
- 1 July 2015
- journal article
- Published by Georg Thieme Verlag KG in European Journal of Dentistry
- Vol. 09 (03), 364-372
- https://doi.org/10.4103/1305-7456.163238
Abstract
Objective: The aim of the present study was to assess the expression of E-cad in oral precancerous lesions and conditions and oral carcinomas in comparison with normal mucosa. Materials and Methods: Total of 50 samples were selected for the study and were categorized into five groups and 10 samples in each group as Group I-oral leukoplakia (OL), Group II-oral lichen planus (OLP), Group III-oral submucous fibrosis (OSMF), Group IV-oral squamous cell carcinoma (OSCC) and Group V-normal oral mucosa (NOM) as control group. All the samples were assessed for the expression of E-cad by immunohistochemical study. Results: Upon assessing the expression of E-cad in OL, OSMF, OLP and OSCC, as majority of the samples with OSCC (90%), OL (80%), OLP (70%) and OSMF (60%) showed mild to moderate expression of E-cad staining, which was suggestive of reduction in dysplastic cells on comparison to NOM cells. This difference in expression and variation of E-cad upon comparison with normal mucosa was statistically significant (P < 0.001). Conclusion: There is significant (P < 0.001) variation of expression of E-cad with the histopathological dysplasia of the oral precancerous lesions and conditions, and the tumor differentiation of the oral cancers. However, there was no correlation of the degree of loss of expression of E-cad with the degree of dysplasia or the tumor differentiation of oral cancers. We conclude with our study that, there is a variation in the expression of E-cad but its value as a prognostic marker is questionable.Keywords
This publication has 21 references indexed in Scilit:
- Clinical Significance of Altered Expression of β-Catenin and E-Cadherin in Oral Dysplasia and Cancer: Potential Link with ALCAM ExpressionPLOS ONE, 2013
- Assessment of malignant potential of oral submucous fibrosis through evaluation of p63, E-cadherin and CD105 expressionJournal of Clinical Pathology, 2010
- Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of managementOral Oncology, 2009
- Decreased expression of the p63 related proteins β-catenin, E-cadherin and EGFR in oral lichen planusOral Oncology, 2008
- The study of E-cadherine and CD44 immunoexpression in oral squamous cell carcinoma.2008
- DNA content, Cyclooxygenase-2 expression and loss of E-cadherin expression do not predict risk of malignant transformation in oral lichen planusEuropean Archives of Oto-Rhino-Laryngology, 2007
- Reduced E-cadherin expression is an indicator of unfavourable prognosis in oral squamous cell carcinomaOral Oncology, 2006
- E-cadherin—catenin cell—cell adhesion complex and human cancerBritish Journal of Surgery, 2000
- Immunohistochemical study of desmosomes in oral squamous cell carcinoma: correlation with cytokeratin and E-cadherin staining, and with tumour behaviourThe Journal of Pathology, 1998
- Cadherin and catenin biology represent a global mechanism for epithelial cancer progression.Molecular Pathology, 1997